[1] 中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018更新版).实用肝脏病杂志,2018,21:177-186.
[2] 陈梦绮,范建高.美国非酒精性脂肪性肝病诊断与治疗临床实践指南简介.实用肝脏病杂志,2022,25(5):S16-S18.
[3] Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol,2021,18:223-238.
[4] Alam S, Kabir J, Mustafa G, Gupta U, et al. Effect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: A 1-year randomized control trial. Saudi JGastroenterol,2016,22:69-76.
[5] Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Angiotensin-receptorblockers as therapy for mild-tomoderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol, 2009,15:942-54.
[6] Leung PS. The physiology of a local renin-angiotensin system in the pancreas. The Journal of physiology, 2007, 580:31.
[7] Bataller R, Sancho-Bru P, Gines P, et al. Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology,2003,125:117-125.
[8] Bataller R, Gabele E, Parsons CJ, Morris T, Yang L, Schoonhoven R, et al.?Systemic infusion of angiotensin II exacerbates liver fibrosis in bile duct-ligated rats. Hepatology,2005,41:1046-1055.
[9] James PA, Oparil S, Carter BL,et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA, 2014,311:507-20.
[10] Saber S, Mahmoud AAA, Goda R, et al. Perindopril, fosinopril and losartan inhibited the progression of diethylnitrosamine-induced hepatocellular carcinoma in mice via the inactivation of nuclear transcription factor kappa-B. Toxicol Lett,2018,295:32-40.
[11] Kudo H, Yata Y, Takahara T, et al. Telmisartan attenuates progression of steatohepatitis in mice: role of hepatic macrophage infiltration and effects on adipose tissue. Liver Int,2009,29:988-996.
[12] Moreno M, Gonzalo T, Kok RJ, et al. Reduction of advanced liver fibrosis by shortterm targeted delivery of an angiotensin receptor blocker to hepatic stellate cells in rats. Hepatology,2010,51:942-952.
[13] Ahmadian E, Khosroushahi AY, Eftekhari A, et al. Novel angiotensin receptor blocker, azilsartan induces oxidative stress and NFkB-mediated apoptosis in hepatocellular carcinoma cell line HepG2. Biomed Pharmacother,2018,99:939-946.
[14] Goh GB, Pagadala MR, Dasarathy J, et al. Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease. Liver Int,2015,35:979-985.
[15] Noureddin N, Noureddin M, Singh A, et al. Progression of Nonalcoholic Fatty Liver Disease-Associated Fibrosis in a Large Cohort of Patients with Type 2 Diabetes. Dig Dis Sci, 2022,67:1379-1388.
[16] Facciorusso A, Del Prete V, Crucinio N, et al. Angiotensin receptor blockers improve survival outcomes after radiofrequency ablation in hepatocarcinoma patients. J Gastroenterol Hepatol,2015,30:1643-1650.
[17] Yoshiji H, Noguchi R, Ikenaka Y, et al. Soluble VEGF receptor-2 may be a predictive marker of antiangiogenic therapy with clinically available safe agents. OncolLett,2011,2:69-73.
[18] Zhang X, Wong G-H, Yip T-F, Tse Y-K, Liang LY, Hui V-K, et al. Angiotensin-converting enzyme inhibitors prevent liverrelated events in nonalcoholic fatty liver disease. Hepatology,2022,76:469-482.
[19] 袁平戈,陈文雯. 非酒精性脂肪性肝炎新药研发临床思考. 实用肝脏病杂志,2021,24(3):305-307. |
